Zolpimist TGA, page-19

No communications from the company re how they are working, not working again shows the lack of respect that Hopper and Baker have for shareholders.

The outcome of the TGA on Zolpimist now over due, no up date on reason why because from my understanding the only way it could be delay is failure by SUD to give required information on time.

Its time for them to come clean, its no good putting out spin and not at least delivering something.currently nothing being delivered. not one product approved in their territories.

The fact that we have had no up date on Teva's application with is now 16 months late is again a sad reflection on Hopper and Baker.




30 March 2020
Dear Shareholder(s),
Update to Shareholders
We have been deciding whether to write to you in regard to your company’s position in these tumultuous
times and at first was hesitant to do so as we’ve all been inundated, nay buried, with information from all
points on the compass, health, political and economic.
After some serious thought though we decided that a brief update as to how we’re dealing with the
situation would be in our shared interests. Our fiduciary responsibility is to keep you and the market
informed, regardless the tempest that blows across our bows. Let us say in the simplest fashion, we are
still doing deals to bring your company to its potential and our research is going full bore.
The need for personal connection is important. The global shock is hurting all of us in some way or other
but our SUDA team, with roots firmly embedded in drug discovery and delivery, has the added impetus
that we will continue to work towards the greater good by steering the company through the challenges
to come.
That is our personal commitment to you.
On a tactical basis we have enforced the distance rule and established a work from home connection
when required. We are abiding by the draconic, but necessary, new rules that govern our day to day work
ethic. It will not however be diminished.
We have also been in dialogue with our national and international partners as they assess impacts on
their core business activities and we assess how best we can continue to work together here and abroad.
We are continuing to work through and promote these projects, not the least of which was our recent
announcement that we had signed a new agreement with Mitsubishi Tanabe Pharma Korea for the license
and supply of ZolpiMist™. A significant deal and one we are proud of.
This was not meant to be anything else but an acknowledgement that your investment with us is
something we take very seriously and from the Board and all of us here at Team SUDA, we extend our
personal hope that during this difficult time you and your family will be safe and protected. You can rest
assured that we are continuing to work and create value for you, our shareholder.
With kind regards,